• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma

    Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases. In addition to the successful raise, Predicta also announced the appointment of Brian McKernan as CEO.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251001161796/en/

    Predicta Biosciences' CEO Brian McKernan

    Predicta Biosciences' CEO Brian McKernan

    "It's an honor to join Predicta and our strong team of leading oncologists, scientists and proven operators using leading-edge genomics to help patients on a diagnostic and therapeutic basis today," said McKernan. "Predicta is already allowing clinicians to better understand and predict multiple myeloma patients' conditions, and how they might respond to different treatment options. Ultimately, Predicta's goal is to expand beyond diagnostics, and this funding will accelerate our path to bringing new precision therapeutics to market by leveraging our one-of-a-kind genomic and immune profiling data."

    McKernan is a three-time biotech founder and experienced CEO, having most recently served as CEO at Fluent BioSciences, which was acquired by Illumina (NASDAQ:ILMN) last year. Several of his companies were significant contributors to the NHGRI's Human Genome Project, as well as key participants in the global effort to curate gene mutation associations for neurological disease conditions. McKernan previously served as the Chairman of the Board of the Analytical Life Sciences and Diagnostic Association and holds an MBA in Finance from Columbia Business School.

    "In the era of precision therapeutics, there is an urgent need for equally precise diagnostics in multiple myeloma and other blood cancers. While many patients are now receiving advanced immunotherapies such as CAR-T cells and bispecific antibodies, clinicians often lack critical insights into the mutation or deletion status of key targets like BCMA or GPRC5D before initiating treatment. Having this knowledge upfront can be transformative - allowing physicians to identify patients unlikely to respond, avoid unnecessary toxicity, and ensure therapies are directed where they will have the greatest impact," said Irene Ghobrial, MD, co-founder of Predicta.

    Predicta's mission is to overcome the numerous limitations in the diagnosis and prognosis of common blood cancers and autoimmune diseases. For blood cancers with no cure, including multiple myeloma, accurate and sensitive testing options for early detection have remained out of reach. In April, Predicta launched its first Laboratory Developed Test (LDT): GenoPredicta, which can use either peripheral blood or bone marrow, and can be ordered by physicians to molecularly diagnose individuals who have or are at risk for multiple myeloma and inform therapeutic management. Predicta is already collaborating closely with leading providers and patient advocacy groups, including the HealthTree Foundation.

    "Predicta stands out among early-stage biotech companies because of its immediate clinical impact and its enormous future potential," said Ann DeWitt, General Partner at Engine Ventures and Predicta Board member. "With Brian McKernan's deep experience in commercializing scientific innovation—combined with the founding team's world-class clinical, genomic, and analytical expertise, we're entering a new phase of growth to meet the urgent unmet needs of patients living with blood cancers and autoimmune conditions."

    About Predicta Biosciences

    Founded by leading cancer genomics researchers and clinicians, Predicta is a precision oncology company developing novel diagnostic and therapeutic products. The company's non-invasive diagnostics initially focus on multiple myeloma, equipping physicians with the unique ability to determine the likelihood of a patient responding to immunotherapies. For more information, visit www.predictabiosciences.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251001161796/en/

    Media Contact

    Kerry Walker

    [email protected]

    Get the next $ILMN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    2/10/2025$130.00 → $100.00Equal Weight → Underweight
    Barclays
    2/7/2025$177.00 → $140.00Buy → Hold
    TD Cowen
    12/11/2024$190.00 → $165.00Buy → Neutral
    Citigroup
    11/12/2024$156.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ILMN
    SEC Filings

    View All

    SEC Form 10-Q filed by Illumina Inc.

    10-Q - ILLUMINA, INC. (0001110803) (Filer)

    8/1/25 5:24:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    7/31/25 4:11:41 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Illumina Inc.

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/25 9:24:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina launches new business to accelerate technology and data-driven discovery

    New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, under

    10/1/25 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina advances personalized cancer care with new pharma development partnerships

    Illumina and pharma partners will develop companion diagnostics for historically important KRAS biomarker SAN DIEGO, Sept. 23, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ:ILMN) will partner with multiple global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight™ Oncology (TSO) Comprehensive genomic profiling test. The continued expansion of tumor-agnostic CDx claims underscores Illumina's commitment to advance access for patients to precision oncology care by generating standardized, globally distributable tests. The new companion diagnostic partnerships will focus on KRAS alterations, which are known to cause uncontrolled cell growth, leading to cancer.

    9/23/25 9:15:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Executive Officer Thaysen Jacob bought $998,674 worth of shares (12,350 units at $80.86), increasing direct ownership by 17% to 83,390 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:18:28 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Thaysen Jacob bought $991,672 worth of shares (7,330 units at $135.29), increasing direct ownership by 97% to 14,861 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/26/24 8:57:29 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Illumina downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Illumina from Outperform to Neutral and set a new price target of $94.00

    8/12/25 7:55:50 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina downgraded by Scotiabank with a new price target

    Scotiabank downgraded Illumina from Sector Outperform to Sector Perform and set a new price target of $125.00

    7/11/25 8:11:04 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Citigroup reiterated coverage on Illumina with a new price target

    Citigroup reiterated coverage of Illumina with a rating of Neutral and set a new price target of $90.00 from $130.00 previously

    3/4/25 8:10:42 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 287 shares, decreasing direct ownership by 0.85% to 33,546 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    9/9/25 7:01:47 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Commercial Officer Cunningham Everett covered exercise/tax liability with 4,248 shares, decreasing direct ownership by 9% to 41,942 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/8/25 5:59:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 307 shares, increasing direct ownership by 4% to 8,137 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/25 4:26:43 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine

    Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO, Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN), and Nashville Biosciences, LLC (NashBio), today announced Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (Alnylam) as a member of the Alliance for Genomic Discovery (AGD). Alnylam, a pioneer in RNA interference (RNAi) therapeutics, will utilize the AGD clinical genomic database to derive real-world insights and accelerate drug target discovery.

    9/18/25 9:15:00 AM ET
    $ALNY
    $ILMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    BioStem Technologies Appoints Brandon Poe as Chief Financial Officer

    POMPANO BEACH, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC:BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced the appointment of Brandon Poe as its Chief Financial Officer (CFO). Mr. Poe has served on BioStem's Board of Directors since 2022. Michael Fortunato, the Company's prior CFO, has assumed the role of Chief Accounting Officer. "I'm excited to welcome Brandon as CFO during this pivotal period of growth and innovation for BioStem," said Jason Matuszewski, Chairman and CEO. "Brandon brings proven financial leader

    8/14/25 4:01:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina Reports Financial Results for Second Quarter of Fiscal Year 2025

    Revenue of $1.06 billion for Q2 2025, down 3% from Q2 2024 on both a reported and constant currency basisGAAP operating margin of 20.2% and non-GAAP operating margin of 23.8% for Q2 2025GAAP diluted EPS of $1.49 and non-GAAP diluted EPS of $1.19 for Q2 2025Cash provided by operations of $234 million and free cash flow of $204 million for Q2 2025For fiscal year 2025, we now expect:Total company constant currency revenue decline in the range of (2.5%) to (0.5%), up from (3%) to (1%) previouslyNon-GAAP operating margin of approximately 22% - 22.5%, up from 21.5% - 22.0% previouslyNon-GAAP diluted EPS in the range of $4.45 - $4.55, an increase from our May guidance of $4.20 - $4.30. This include

    7/31/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Second Quarter 2025 Financial Results on Thursday, July 31, 2025

    SAN DIEGO, July 10, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2025 following the close of market on Thursday, July 31, 2025. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 31, 2025. Interested parties may access the live webcast via the Investor Info section of Illumina's

    7/10/25 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Infinity Bio Closes $8M Series A Financing Led by Illumina Ventures to Expand Leadership in Antibody Reactome Profiling

    Investment supports platform innovation, commercial scaling, and new service development; Infinity acquires the assets of Serimmune, Inc. Infinity Bio, a biotechnology company pioneering technologies to map immune responses at scale, today announced the successful closing of an $8 million Series A financing round. The round was led by Illumina Ventures, with participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund. As part of the strategic plan to broaden its suite of service offerings, Infinity Bio has acquired the assets of Serimmune, Inc., which was founded in 2014 to provide unbiased antibody reactome services. New MIPSA™ service offerings, including EnviroSI

    6/18/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care